Geindreau M, Pignol C, Coënon L, Varin A, Racoeur C, Milian L, Roger N, Chalmin F, Vernet T, Alibert L, Bellaye PS, Thibaudin M, Louis C, Wicks I, Truntzer C, Boidot R, Paul C, Lamarthée B, Vegran F, Ghiringhelli F, Bruchard M

J Immunother Cancer. 2026 06 22;14(6):

The intrinsic expression of NLRP3 in Th17 cells promotes their protumor activity and conversion into Tregs.

Accogli T, Hibos C, Milian L, Geindreau M, Richard C, Humblin E, Mary R, Chevrier S, Jacquin E, Bernard A, Chalmin F, Paul C, Ryffel B, Apetoh L, Boidot R, Bruchard M, Ghiringhelli F, Vegran F

Cell Mol Immunol. 2025 04 7;:

NIR-II aza-BODIPY Platform for the Development of a Fluorescent Antibody Drug Conjugate.

Chazeau E, Pipier A, Wegner KD, Ghiringhelli F, Sancey L, Paul C, Goze C

J Med Chem. 2025 03 28;:

From the design of innovative Ti-Pt heterometallic complexes to the development of highly anti-proliferative water-soluble cationic titanocenes.

Trommenschlager A, Mabrouk N, Racoeur C, Godard A, Balan C, Dubrez L, Bettaieb A, Husson J, Le Gendre P, Paul C, Bodio E

Chembiochem. 2024 05 15;:e202400099

Comparison of the In Vitro and In Vivo Behavior of a Series of NIR-II-Emitting Aza-BODIPYs Containing Different Water-Solubilizing Groups and Their Trastuzumab Antibody Conjugates.

Chazeau E, Fabre C, Privat M, Godard A, Racoeur C, Bodio E, Busser B, Wegner KD, Sancey L, Paul C, Goze C

J Med Chem. 2024 02 23;:

Development of an Immuno-SPECT/Fluorescent Bimodal Tracer Targeting Human or Murine PD-L1 on Preclinical Models.

Privat M, Massot A, Hermetet F, Al Sabea H, Racoeur C, Mabrouk N, Cordonnier M, Moreau M, Collin B, Bettaieb A, Denat F, Bodio E, Bellaye PS, Goze C, Paul C

J Med Chem. 2024 01 25;:

GTN Enhances Antitumor Effects of Doxorubicin in TNBC by Targeting the Immunosuppressive Activity of PMN-MDSC.

Mabrouk N, Racoeur C, Shan J, Massot A, Ghione S, Privat M, Dondaine L, Ballot E, Truntzer C, Boidot R, Hermetet F, Derangère V, Bruchard M, Végran F, Chouchane L, Ghiringhelli F, Bettaieb A, Paul C

Cancers (Basel). 2023 06 9;15(12):

NIR-II Aza-BODIPY Dyes Bioconjugated to Monoclonal Antibody Trastuzumab for Selective Imaging of HER2-Positive Ovarian Cancer.

Godard A, Kalot G, Privat M, Bendellaa M, Busser B, Wegner KD, Denat F, Le Guével X, Coll JL, Paul C, Bodio E, Goze C, Sancey L

J Med Chem. 2023 03 30;:

First Comparison Study of the and Properties of a Randomly and Site-Specifically Conjugated SPECT/NIRF Monomolecular Multimodal Imaging Probe (MOMIP) Based on an aza-BODIPY Fluorophore.

Privat M, Bellaye PS, Chazeau E, Racoeur C, Adumeau P, Vivier D, Bernhard C, Moreau M, Collin B, Bettaieb A, Denat F, Bodio E, Paul C, Goze C

Bioconjug Chem. 2023 03 27;:

cIAP1/TRAF2 interplay promotes tumor growth through the activation of STAT3.

Dumétier B, Zadoroznyj A, Berthelet J, Causse S, Allègre J, Bourgeois P, Cattin F, Racoeur C, Paul C, Garrido C, Dubrez L

Oncogene. 2022 11 18;:

Development of Anti-LRRC15 Small Fragments for Imaging Purposes Using a Phage-Display ScFv Approach.

Baurand PE, Balland J, Reynas C, Ramseyer M, Vivier D, Bellaye PS, Collin B, Paul C, Denat F, Asgarov K, Pallandre JR, Ringenbach L

Int J Mol Sci. 2022 10 21;23(20):

Lipoprotein interactions with water-soluble NIR-II emitting aza-BODIPYs boost the fluorescence signal and favor selective tumor targeting.

Kalot G, Godard A, Busser B, Bendellaa M, Dalonneau F, Paul C, Le Guével X, Josserand V, Coll JL, Denat F, Bodio E, Goze C, Gautier T, Sancey L

Biomater Sci. 2022 09 23;:

Protein Kinase Inhibitor-Mediated Immunoprophylactic and Immunotherapeutic Control of Colon Cancer.

Ghione S, Racoeur C, Mabrouk N, Shan J, Groetz E, Ballot E, Truntzer C, Chouchane L, Végran F, Paul C, Plenchette S, Bettaieb A

Front Immunol. 2022 04 28;13:875764

Impact of Lipid Metabolism on Antitumor Immune Response.

Mabrouk N, Lecoeur B, Bettaieb A, Paul C, Végran F

Cancers (Basel). 2022 Apr 6;14(7):

Conception and evaluation of fluorescent phosphine-gold complexes: from synthesis to in vivo investigations.

Rousselle B, Massot A, Privat M, Dondaine L, Trommenschlager A, Bouyer F, Bayardon J, Ghiringhelli F, Bettaieb A, Goze C, Paul C, Malacea-Kabbara R, Bodio E

ChemMedChem. 2022 Mar 7;:

Recruitment and activation of type 3 innate lymphoid cells promote antitumor immune responses.

Bruchard M, Geindreau M, Perrichet A, Truntzer C, Ballot E, Boidot R, Racoeur C, Barsac E, Chalmin F, Hibos C, Baranek T, Paget C, Ryffel B, Rébé C, Paul C, Végran F, Ghiringhelli F

Nat Immunol. 2022 Feb;23(2):262-274

Development of an Easily Bioconjugatable Water-Soluble Single-Photon Emission-Computed Tomography/Optical Imaging Bimodal Imaging Probe Based on the aza-BODIPY Fluorophore.

Privat M, Bellaye PS, Lescure R, Massot A, Baffroy O, Moreau M, Racoeur C, Marcion G, Denat F, Bettaieb A, Collin B, Bodio E, Paul C, Goze C

J Med Chem. 2021 Aug 2;:

Near-infrared emitting fluorescent homobimetallic gold(I) complexes displaying promising in vitro and in vivo therapeutic properties.

Lescure R, Privat M, Pliquett J, Massot A, Baffroy O, Busser B, Bellaye PS, Collin B, Denat F, Bettaïeb A, Sancey L, Paul C, Goze C, Bodio E

Eur J Med Chem. 2021 Apr 19;220:113483

Senescence and Cancer: Role of Nitric Oxide (NO) in SASP.

Mabrouk N, Ghione S, Laurens V, Plenchette S, Bettaieb A, Paul C

Cancers (Basel). 2020 May 2;12(5):

Protein kinase inhibitor-based cancer therapies: considering the potential of nitric oxide (NO) to improve cancer treatment.

Ghione S, Mabrouk N, Paul C, Bettaieb A, Plenchette S

Biochem. Pharmacol.. 2020 Feb 12;:113855

Rapid synthesis and anti-proliferative properties of polyazamacrocycle-based bi- and tetra-gold(I) phosphine dithiocarbamate complexes.

Flores O, Velic D, Mabrouk N, Bettaieb A, Tomasoni C, Robert JM, Paul C, Goze C, Roussakis C, Bodio E

Chembiochem. 2019 Apr 10;:

A promising family of fluorescent water-soluble aza-BODIPY dyes for in vivo molecular imaging.

Pliquett J, Dubois A, Racoeur C, Mabrouk N, Amor S, Lescure R, Bettaieb A, Collin B, Bernhard C, Denat F, Bellaye PS, Paul C, Bodio E, Goze C

Bioconjug. Chem.. 2019 Jan 7;:

Polysaccharide Chain Length of Lipopolysaccharides From Minnesota Is a Determinant of Aggregate Stability, Plasma Residence Time and Proinflammatory Propensity .

Sali W, Patoli D, Pais de Barros JP, Labbé J, Deckert V, Duhéron V, Le Guern N, Blache D, Chaumont D, Lesniewska E, Gasquet B, Paul C, Moreau M, Denat F, Masson D, Lagrost L, Gautier T

Front Microbiol. 2019 ;10:1774

Gold(I)-coumarin-caffeine-based complexes as new potential anti-inflammatory and anticancer trackable agents.

Trommenschlager A, Chotard F, Bertrand B, Amor S, Richard P, Bettaïeb A, Paul C, Connat JL, Le Gendre P, Bodio E

ChemMedChem. 2018 Sep 11;:

Design of a multifunctionalizable BODIPY platform for the facile elaboration of a large series of gold(i)-based optical theranostics.

Pliquett J, Amor S, Ponce-Vargas M, Laly M, Racoeur C, Rousselin Y, Denat F, Bettaïeb A, Fleurat-Lessard P, Paul C, Goze C, Bodio E

Dalton Trans. 2018 Jul 27;:

Tumor-derived granzyme B-expressing neutrophils acquire antitumor potential after lipid A treatment.

Martin A, Seignez C, Racoeur C, Isambert N, Mabrouk N, Scagliarini A, Reveneau S, Arnould L, Bettaieb A, Jeannin JF, Paul C

Oncotarget. 2018 Jun 19;9(47):28364-28378

PD-1/PD-L1 pathway: an adaptive immune resistance mechanism to immunogenic chemotherapy in colorectal cancer.

Dosset M, Vargas TR, Lagrange A, Boidot R, Végran F, Roussey A, Chalmin F, Dondaine L, Paul C, Marie-Joseph EL, Martin F, Ryffel B, Borg C, Adotévi O, Ghiringhelli F, Apetoh L

Oncoimmunology. 2018 ;7(6):e1433981

Gold(i)-BODIPY-imidazole bimetallic complexes as new potential anti-inflammatory and anticancer trackable agents.

Trommenschlager A, Chotard F, Bertrand B, Amor S, Dondaine L, Picquet M, Richard P, Bettaïeb A, Le Gendre P, Paul C, Goze C, Bodio E

Dalton Trans. 2017 Jun;:

Precision medicine in breast cancer: reality or utopia?

Bettaieb A, Paul C, Plenchette S, Shan J, Chouchane L, Ghiringhelli F

J Transl Med. 2017 Jun;15(1):139

Exploration of Fas S-Nitrosylation by the Biotin Switch Assay.

Bettaieb A, Paul C, Plenchette S

Methods Mol. Biol.. 2017 ;1557:199-206

Clinical significance of T-bet, GATA-3, and Bcl-6 transcription factor expression in bladder carcinoma.

Bahria-Sediki IB, Yousfi N, Paul C, Chebil M, Cherif M, Zermani R, El Gaaied AB, Bettaieb A

J Transl Med. 2016 May;14(1):144

TLR4/IFNγ pathways induce tumor regression via NOS II-dependent NO and ROS production in murine breast cancer models.

Lamrani M, Sassi N, Paul C, Yousfi N, Boucher JL, Gauthier N, Labbé J, Seignez C, Racoeur C, Athias A, Guerreiro R, Vergely C, Rochette L, Bettaieb A, Jeannin JF

Oncoimmunology. 2016 May;5(5):e1123369

Anticancer Agents: Does a Phosphonium Behave Like a Gold(I) Phosphine Complex? Let a "Smart" Probe Answer!

Ali M, Dondaine L, Adolle A, Sampaio C, Chotard F, Richard P, Denat F, Bettaieb A, Le Gendre P, Laurens V, Goze C, Paul C, Bodio E

J Med Chem. 2015 Jun 11;58(11):4521-8

Towards the elaboration of new gold-based optical theranostics.

Doulain PE, Decréau R, Racoeur C, Goncalves V, Dubrez L, Bettaieb A, Le Gendre P, Denat F, Paul C, Goze C, Bodio E

Dalton Trans. 2015 Mar;44(11):4874-83

H89 enhances the sensitivity of cancer cells to glyceryl trinitrate through a purinergic receptor-dependent pathway.

Cortier M, Boina-Ali R, Racoeur C, Paul C, Solary E, Jeannin JF, Bettaieb A

Oncotarget. 2015 Feb 4.

Gold-phosphine-porphyrin as potential metal-based theranostics.

Tasan S, Licona C, Doulain PE, Michelin C, Gros CP, Le Gendre P, Harvey PD, Paul C, Gaiddon C, Bodio E

J Biol Inorg Chem. 2015 Jan;20(1):143-54

cIAP1 regulates TNF-mediated cdc42 activation and filopodia formation.

Marivin A, Berthelet J, Cartier J, Paul C, Gemble S, Morizot A, Boireau W, Saleh M, Bertoglio J, Solary E, Dubrez L

Oncogene. 2014 Nov 27;33(48):5534-45

Senescence of tumor cells induced by oxaliplatin increases the efficiency of a lipid A immunotherapy via the recruitment of neutrophils.

Seignez C, Martin A, Rollet CE, Racoeur C, Scagliarini A, Jeannin JF, Bettaieb A, Paul C

Oncotarget. 2014 Nov 30;5(22):11442-51.

Alcohol consumption and psoriasis: a systematic literature review.

Brenaut E, Horreau C, Pouplard C, Barnetche T, Paul C, Richard MA, Joly P, Le Maitre M, Aractingi S, Aubin F, Cribier B, Jullien D, Ortonne JP, Misery L

J Eur Acad Dermatol Venereol. 2013 Aug;27 Suppl 3:30-5

Cardiovascular morbidity and mortality in psoriasis and psoriatic arthritis: a systematic literature review.

Horreau C, Pouplard C, Brenaut E, Barnetche T, Misery L, Cribier B, Jullien D, Aractingi S, Aubin F, Joly P, Le Maitre M, Ortonne JP, Paul C, Richard MA

J Eur Acad Dermatol Venereol. 2013 Aug;27 Suppl 3:12-29

Psoriasis, cardiovascular events, cancer risk and alcohol use: evidence-based recommendations based on systematic review and expert opinion.

Richard MA, Barnetche T, Horreau C, Brenaut E, Pouplard C, Aractingi S, Aubin F, Cribier B, Joly P, Jullien D, Le Maitre M, Misery L, Ortonne JP, Paul C

J Eur Acad Dermatol Venereol. 2013 Aug;27 Suppl 3:2-11

Risk of cancer in psoriasis: a systematic review and meta-analysis of epidemiological studies.

Pouplard C, Brenaut E, Horreau C, Barnetche T, Misery L, Richard MA, Aractingi S, Aubin F, Cribier B, Joly P, Jullien D, Le Maitre M, Ortonne JP, Paul C

J Eur Acad Dermatol Venereol. 2013 Aug;27 Suppl 3:36-46

The radiosensitization effect of titanate nanotubes as a new tool in radiation therapy for glioblastoma: a proof-of-concept.

Mirjolet C, Papa AL, Crehange G, Raguin O, Seignez C, Paul C, Truc G, Maingon P, Millot N

Radiother Oncol. 2013 Jul;108(1):136-42

Phase I study of OM-174, a lipid A analogue, with assessment of immunological response, in patients with refractory solid tumors.

Isambert N, Fumoleau P, Paul C, Ferrand C, Zanetta S, Bauer J, Ragot K, Lizard G, Jeannin JF, Bardou M

BMC Cancer. 2013 Apr 2;13:172

Fine-tuning nucleophosmin in macrophage differentiation and activation.

Guery L, Benikhlef N, Gautier T, Paul C, Jego G, Dufour E, Jacquel A, Cally R, Manoury B, Vanden Berghe T, Vandenabeele P, Droin N, Solary E

Blood. 2011 Oct 27;118(17):4694-704

Efficacy and safety of oral retinoids in different psoriasis subtypes: a systematic literature review.

Sbidian E, Maza A, Montaudie H, Gallini A, Aractingi S, Aubin F, Cribier B, Joly P, Jullien D, Le Maitre M, Misery L, Richard MA, Paul C, Ortonne JP, Bachelez H

J Eur Acad Dermatol Venereol. 2011 May;25 Suppl 2:28-33

Oral cyclosporin in psoriasis: a systematic review on treatment modalities, risk of kidney toxicity and evidence for use in non-plaque psoriasis.

Maza A, Montaudie H, Sbidian E, Gallini A, Aractingi S, Aubin F, Bachelez H, Cribier B, Joly P, Jullien D, Le Maitre M, Misery L, Richard MA, Ortonne JP, Paul C

J Eur Acad Dermatol Venereol. 2011 May;25 Suppl 2:19-27